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Death	from	lung	cancer	is	one	of	the	most	com-
mon	 types	of	cancer-related	death.	Non-small-cell	
lung	cancer	(NSCLC)	accounts	for	approximately	80%	
of	 lung	 tumors.	All	 the	currently	available	 treatment	
options	for	NSCLC,	including	surgery,	radiation,	and	
chemotherapy,	have	 limited	efficacy	 [1].	Surgery	 is	
not	an	option	 for	 treatment	because	approximately	
65%	of	these	patients	have	advanced-stage	(IIIB/IV)	
disease	at	diagnosis	[1].	In	addition,	NSCLC	is	more	
resistant	 to	chemotherapy	 than	other	 forms	of	can-
cer	 [2].	 Although	 some	progress	 has	been	made	
in	 the	management	of	patients	with	NSCLC,	 there	
is	still	a	need	 to	develop	more	efficacious	methods	
of	 treatment.	Targeted	chemotherapy	 is	 a	modern	
approach	for	the	treatment	of	cancers	because	it	 is	
more	efficacious	and	 less	toxic	than	usual	systemic	
chemotherapy	[3].	
Somatostatin	 (SST)	 is	 a	peptide	hormone,	 the	
cellular	actions	of	which	are	mediated	by	a	family	of	
G-protein-coupled	receptors	(SSTR)	that	has	five	sub-
types:	SSTR1,	SSTR2,	SSTR3,	SSTR4	and	SSTR5	[4].	
Some	investigators	have	reported	that	cells	of	human	
small	cell	lung	cancer	and	NSCLC	overexpress	SSTRs	
[5,	6].	The	precise	nature	of	the	expression	of	SSTRs	
by	NSCLC	cell	lines	remains	controversial.	Ferone	et	
al	[7]	detected	SSTRs	in	Calu-6	cells,	although	nume-
rous	investigators	have	reported	that	many	NSCLC	cell	
lines	do	not	express	SSTRs	[8,	9].	SST	analogs	may	
be	potential	vehicles	for	chemotherapeutic	drugs	used	
to	treat	SSTR-positive	tumors	because	the	binding	of	
SST	to	 its	 receptor	 is	 followed	by	 its	 internalization.	
Therefore,	the	binding	of	an	SST	conjugate	to	cance-
rous	cells	that	express	SSTRs	could	result	in	the	accu-
mulation	of	the	chemotherapeutic	drug	malignant	cells	
[10].	Although	this	putative	mechanism	of	action	has	
not	yet	been	demonstrated	for	SST	analogs	carrying	
cytotoxic	drugs,	the	localization	of	primary	tumors	and	
their	metastases	by	scintigraphy	using	 radiolabeled	
SST	analogs	 lend	strong	support	 for	such	a	of	 this	
mechanism	of	action	[10,	11].	
Paclitaxel	 is	a	diterpenoid	 taxane	derivative	 that	
was	first	isolated	from	Taxus brevifolia	by	Wani	in	1971	
[12].	It	possesses	excellent	antitumor	activity	in	a	wide	
variety	of	tumor	models,	especially	in	NSCLC	[13].	Its	
antitumor	actions	are	attributed	to	its	ability	to	promote	
tubulin	assembly	into	microtubules	[14].	In	the	pres-
ence	of	paclitaxel,	depolymerization	of	the	microtu-
bules	is	inhibited,	thereby	interfering	with	the	G2	and	
M	phases	of	the	cell	cycle	[15].	In	spite	of	its	excellent	
antitumor	activity,	paclitaxel	is	not	cell	specific.
Octreotide	 (SMS	201-995,	SandostatinTM)	 is	 an	
octapeptide	analog	of	endogenous	SST	and	binds	to	
SSTR-2,	SSTR-3	and	SSTR-5	[16].	By	virtue	of	these	
properties,	we	thought	that	octreotide	had	the	poten-
tial	be	a	suitable	vehicle	for	delivering	paclitaxel	to	its	
intracellular	target.	Therefore,	we	developed	a	series	
of	cytotoxic	octreotide	conjugates	 that	contain	pa-
clitaxel	and	evaluated	their	cytotoxicity	in	two	NSCLC	
cell	types,	namely,	Calu-6	cells,	which	are	known	to	
express	SSTRs	and	A549	cells,	whose	expression	of	
SSTRs	is	considered	to	be	low	[17].
MATERIALS AND METHODS
Materials. The	human	NSCLC	A549	cell	line	was	
obtained	from	the	Institute	of	Biochemistry	and	Cell	
Biology,	Shanghai	Institutes	for	Biological	Sciences,	
Chinese	Academy	of	Sciences,	Shanghai.	The	human	
NSCLC	cell	 line	Calu-6	was	purchased	 from	Tianjin	
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Medical	University	Cancer	Institute	(China).	Cultured	
human	fibroblast	cells	were	obtained	from	human	scar	
tissue	and	were	supplied	by	Dr.	Bin	Xu,	of	the	Central	
Laboratory	of	Qilu	Hospital	(China);	and	Dr.	Bin	Xu	had	
got	the	permission	of	Ethical	committee	and	patients’	
agreement	 for	 the	cultured	human	 fibroblast	cells.	
Roswell	Park	Memorial	Institute	Medium	1640	(RPMI),	
fetal	bovine	serum,	and	typsin	were	purchased	from	
Invitrogen;	TRIzol	reagent	and	diethylpyrocarbonate	
(DEPC)	were	purchased	 from	Sangon,	Shanghai;	
RT-PCR	Kit	and	DNA	Marker	DL2000	were	purchased	
from	TaKaRa	Biotechnology	Co.	 Ltd.	 (China); The	
five	SSTR	subtypes	and	β-actin	primers	were	made	
by	 Invitrogen.	Paclitaxel	was	purchased	 from	Man-
fangyuan	Chemical	Industry	Co.,	Ltd.,	China;	Octreo-
tide	was	purchased	from	Zillion	Co.	Ltd.	(China);	and	
benzotriazol-1-yloxy-tris-pyrrolidinophosphonium	
(PyBOP)	was	purchased	from	Shanghai	Medpep	Co.	
Ltd.	(China).	
Synthetic chemistry. The	conjugates	were	syn-
thesized	by	 the	Pharmaceutical	Chemistry	 Institute	
of	Pharmacy	College,	Shandong	University.	Many	
researchers	have	reported	that	the	2’	position	of	pa-
clitaxel	 is	a	suitable	site	 for	 reversible	derivatization	
[18–20].	Structure-activity	studies	on	pacliatxel	 re-
vealed	that	the	C-13	ester	side	chain	and	its	2’-hydroxl	
group	appear	essential	for	tubulin	binding	[13].	This	
information	suggests	that	the	2’	and	7’	position	are	the	
most	suitable	sites	for	reversible	derivatization	[21].	
2’-succinyl-paclitaxel	(WP-06-1)	was	synthesized	by	
the	procedure	described	by	Cavallaro	et	al	[20].	It	was	
activated	by	PyBOP	and	then	coupled	to	octreotide.	
Two	kinds	of	conjugate	were	purified	by	high-perfor-
mance	liquid	chromatography	(HPLC).	WP-06-2A	was	
the	broad	singlet	product	purified	by	HPLC	 (HPLC.	
15.67	min.;	MS.	1998.7;	MW.	1996.27)	and	WP-06-2B	
was	a	pure	singlet	product	purified	by	HPLC	(HPLC.	
20.85min.;	MS.	2892.8;	MW.	2890.19).		
Cell culture. A549	cells	were	cultured	in	RPMI-1640	
that	contained	10%	FBS.	Calu-6	cells	were	cultured	in	
15%	FBS.	Fibroblast	cells	were	cultured	in	RPMI-1640	
medium	 that	contained	20%	fetal	bovine	serum.	All	
culture	media	were	replaced	with	fresh	media	every	
two	to	three	days.	The	cells	were	cultured	at	37	°C	in	
5%	CO2	/95%	air	and	were	used	when	 they	were	 in	
their	growth	phase.	
the detection of SStr mrnA by rt-PCr. 
The	expression	of	SSTR	mRNA	using	RT-PCR	was	
performed	according	to	the	manufacturer’s	instruc-
tions.	Total	RNA	was	extracted	using	TRIzol	reagent.	
An	aliquot	(1	μg)	of	total	RNA	was	reverse	transcribed	
using	AMV-reverse	transcriptase	and	then	amplified	
using	specific	primers	 for	SSTR1,	SSTR2,	SSTR3,	
SSTR4	and	SSTR5	(Table	1).	β-Actin was	used	as	the	
internal	control.	The	PCR	conditions	were	as	follows:	
(I)	denaturing	for	40	s	at	94	°C;	(II)	annealing	for	40	s	
at	55	°C	for	SSTR2	and	SSTR5	or	for	40	s	at	57	°C	for	
SSTR1,	SSTR3	and	SSTR4;	(III)	extension	for	1	min	
at	72	 °C;	and	 (IV)	 final	extension	 for	5	min	at	72	 °C	
cycled	30	times.	The	PCR	products	were	visualized	by	
ethidium	bromide	staining	and	electrophoresis	in	2%	
agarose.	The	optical	density	(OD)	of	the	target	band	
was	corrected	for	the	corresponding β-actin	band.	The	
results	were	expressed	as	the	OD	ratio.	
Table 1. RT-PCR Primers
Index Primers Length(bp)
SSTR-1 Forward 5’-ATGGTGGCCCTCAAGGCCGG-3’
Reverse 5’-CGCGGTGGCGTAATAGTCAA-3’ 318
SSTR-2 Forward 5’-TCCTCTGGAATCCGAGTGGG-3’
Reverse 5’-TTGTCCTGCTTACTGTCACT-3’ 332
SSTR-3 Forward 5’-GGAGAAGACTGAGGAGGAGG-3’
Reverse 5’-TTTCCCCAGGCCCTACAG-3’ 235
SSTR-4 Forward 5’-ATCTTCGCAGACACCAGACC-3’
Reverse 5’-ATCAAGGCTGGTCACGACGA-3’ 321
SSTR-5 Forward 5’-CGTCTTCATCATCTACACGG-3’
Reverse 5’-GGCCAGGTTGACGATGTTGA-3’ 223
β-actin Forward 5’-ATCATGAAGTGTGACGTGGAC-3’
Reverse 5’-AACCGACTGCTGTCACCTTCA-3’ 461
Cell proliferation assay. Cell	proliferation	was	
assessed	by	the	MTT-based	cytotoxicity	assay.	Cells	
were	seeded	at	4000	cells/well	in	96-well	plates,	and	
the	protocol	of	the	MTT	assay	was	the	same	as	that	
described	by	Rivera	et	al.	[22].	
To	investigate	whether	WP-06-1	retains	the	toxicity	
of	paclitaxel,	we	first	treated	A549	cells	with	different	
concentrations	(0.01,	1,	100,	1000	and	10	000	nmol/L)	
of	WP-06-1	and	paclitaxel	for	24	h.	The	cytotoxicity	of	
the	conjugates	in	A549	cells	and	Calu-6	cells	was	then	
assessed	using	concentrations	of	0.01,	1,	100	and	
1000	nmol/L	conjugates	for	24	h,	48	h	and	72	h.
To	determine	whether	WP-06-2A	and	WP-06-2B	
cause	cytotoxicity	by	binding	 to	SSTRs,	A549	cells	
were	pretreated	with	10μmol/L	octreotide	 for	30min	
before	1μmol/L	conjugates	were	added.	 It	 is	known	
that	fibroblasts	are	low-SSTR-expressing	cells	[23,	24].	
Therefore,	we	chose	these	cells	as	the	SSTR-negative	
control	cells.	The	fibroblasts	were	treated	by	different	
concentrations	 (0.01,	1,	100,	 and	1000	nmol/L)	of	
conjugates	and	paclitaxel	for	24	h.
Cell-cycle analysis. Cell	cycle	perturbations	were	
determined	after	a	24	h	treatment	of	1	μmol/L	pacli-
taxel,	WP-02-A,	WP-02-B	by	flow	cytometry	using	a	
Fluorescence-Activated	Cell	Sorter	 (FACS)	 (FC500,	
Beckman	Coulter	Co.	Ltd.,	USA).
Statistical analysis. SPSS	statistical	 software	
(version	12.0)	was	used	for	analyses.	Statistical	signifi-
cance	was	determined	using	the	analysis	of	variance	
(ANOVA).	Data	are	expressed	as	mean	±	 standard	
deviation	 (SD).	Data	were	deemed	statistically	sig-
nificant	at	p	<	0.05.	
RESuLTS 
Expression of SStrs in A549 cells, Calu-6 cells 
and fibroblasts. The	expression	of	mRNA	for	SSTR1,	
SSTR2,	SSTR4	and	SSTR5	was	detected	in	A549	and	
Calu-6	cells.	 In	the	A549	cell	 line,	the	expression	of	
SSTR2	mRNA	was	conspicuous,	whereas	the	expres-
sion	of	SSTR5	mRNA	was	weak.	The	expression	of	
SSTR5	mRNA	 in	Calu-6	cells	was	obvious,	but	 the	
expression	of	SSTR2	mRNA	was	not	marked	(Fig.	1).	
Neither	cell	line	expressed	SSTR3	mRNA	nor	mRNA	
was	detected	in	fibroblasts	for	any	subtype	of	SSTR.
188	 Experimental	Oncology	29,	186–191,	2007	(September)
fig. 1. The detection	of	mRNA	for	SSTRs	in	A549	(a)	and	Calu-6	
(b)	cells	by	RT-PCR.	Calu-6	and	A549	cells	did	not	express	the	
mRNA	for	SSTR-3.	Lane M, marker; Lane 1, SSTR-1; Lane 2,	 	 	 	 	 	 	  
SSTR-2;	Lane	3,	SSTR-3;	Lane	4,	SSTR-4;	Lane	5,	SSTR-5;	
Lane	6, β-actin
toxicity of the WP-06-1. There	were	no	diffe-
rences	in	the	cytotoxic	activity	of	WP-06-01	and	placli-
taxel	 in	A549	cells	 (Table	2).	This	 result	established	
that	the	succinyl	group	on	the	2’	position	of	paclitaxel	
is	not	essential	 for	 its	 toxicity.	WP-06-1	 retains	 the	
toxicity	of	paclitaxel.
Table 2. Cell viability of A549 cells after a 24 h treatment of WP-06-1 and 
paclitaxel (%, mean ± SD)
Concentration (nmol/L)
0 0.01 1 100 1000 10 000
Paclitaxel 100 84.4 ± 
5.3
82.5 ± 
3.1
73.6 ± 
6.7
64.9 ± 
6.3
69.2 ± 
5.6
WP-06-1 100 85.3 ± 
1.3
82.5 ± 
6.2
70.3 ± 
4.8
72.9 ± 
5.1
65.2 ± 
2.2
toxicity of the conjugates in SStr-positive 
cells. The	conjugates	 inhibited	 the	growth	of	A549	
and	Calu-6	cells	in	a	concentration-dependent	man-
ner	(Fig.	2,	a	and	b).	WP-06-2B	was	significantly	more	
cytotoxic	 than	WP-06-2A	and	paclitaxel	at	 low	con-
centrations	(0.01,	1	and	100	nmol/L)	in	A549	cells	(p <	
0.05).	At	10	μmol/L,	all	the	drugs	caused	precipitates	
in	the	culture	media.	There	were	no	differences	in	the	
viability	of	A549	cells	when	treated	with	1	μmol/L	or	
10	μmol/L	paclitaxel.	However,	10	μmol/L	WP-06-2B	
and	WP-06-2A	were	more	cytotoxic	than	that	observed	
at	10	μmol/L	paclitaxel	in	A549	cells	(p <	0.05).	At	this	
concentration,	the	viability	of	A549	cells	was	45.7 ± 
6.9%	with	WP-06-2A,	46.7 ± 9.0%	with	WP-06-2B	
treatment	whereas	for	paclitaxel,	viability	was	69.2 ± 
5.6%	(see	Fig.	2,	a).	In	Calu-6	cells,	the	two	conjugates	
and	paclitaxel	caused	concentration-dependent	cyto-
toxicity	to	the	same	degree	(see	Fig.	2,	b).
The	conjugates	also	inhibited	the	growth	of	A549	
and	Calu-6	cells	in	a	time-dependent	manner	(Fig.	2,	c	
and	2,	d).	In	A549	cells,	100	nmol/L	WP-06-2B	showed	
higher	cytotoxicity	 than	WP-06-2A	and	paclitaxel	at	
24	h.	When	the	exposure	times	to	the	conjugates	and	
paclitaxel	were	extended	to	48–72	h,	 there	were	no	
differences	 in	 the	 relative	 viability	or	cytotoxicity	 in	
A549	cells	(see	Fig.	2,	c).	In	Calu-6	cells,	100	nmol/L	
WP-06-2B	showed	 less	cytotoxicity	 than	WP-06-2A	
and	paclitaxel	at	all	exposure	times	(see	Fig.	2,	d).
fig. 2. The	conjugates	inhibited	the	growth	of	A549	and	Calu-6	
cells.	Figures	a	and	b	show	that	24	h	exposure	of	A549	cells	(a) 
and	Calu-6	cells	(b) to	the	conjugates	inhibited	cell	growth	in	a	
concentration-dependent	manner.	Data	of	treatment	with	higher	
concentrations	are	not	shown,	due	to	precipitation	in	cell	media.	
Figures c	and	d	show	the	 time-dependent	 inhibitory	effect	of	
100	nmol/L	conjugates	on	the	growth	of	A549	(c)	and	Calu-6	(d)	
cells.	(Mean	±	SD.	*p <	0.05	vs	PTX;	∆p <	0.05	vs	WP-06-2A)	
Octreotide	modified	the	cytotoxicity	of	WP-06-2A	and	
WP-06-2B,	but	ameliorate	the	cytotoxicity	of	paclitaxel.	
Following	24	h	exposure	to	1	μmol/L	WP-06-2A,	the	vi-
ability	of	A549	cells	was	55.4	±	9.8%.	Pretreatment	for	
30	min	with	10	μmol/L	octreotide	increased	the	viability	to	
63.7	±	5.4%.	A	similar	result	was	seen	when	1	μmol/L	WP-
06-2B	was	used.	Pretreatment	with	octreotide	increased	
cell	viability	from	55.8	±	6.1%	to	71.8	±	9.6%.	In	contrast,	
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pretreatment	with	octreotide	exacerbated	the	cytotoxic	
effects	of	1	μmol/L	paclitaxel	(59.2	±	6.4%	vs	64.9	±	
6.3%;	p <	0.05)	(Table	3).	Pretreatment	of	octreotide	
therefore	ameliorates	the	cytotoxicity	of	the	conjugates	
but	potentiates	the	cytotoxicity	of	paclitaxel.	
Table 3. Cell viability of A549 cells after a 24h treatment with/without 
10 μmol/L octreotide pretreated for 30 min (%, mean ± SD)
Control Paclitaxel WP-06-2A WP-06-2B
Non-pretreated 100 64.9 ± 6.3 55.4 ± 9.8 55.8 ± 6.1
OCT pretreated 87.9 ± 9.9 59.2 ± 6.4* 63.7 ± 5.4* 71.8 ± 9.6*
*p < 0.05, vs Non-pretreated. 
toxicity of the conjugates in fibroblasts 
(SStr-negative) cells. Changes	in	cell	morphology	
were	observed	in	fibroblasts	following	24	h	exposure	to	
1	μmol/L	paclitaxel	(data	is	not	shown).	These	changes	
were	associated	with	a	reduction	in	cell	viability	(64.7	±	
8.6%).	 Exposure	 to	 1	 μmol/L	 conjugates	 for	 24	h	
caused	no	overt	changes	in	cell	morphology,	but	was	
associated	with	moderate	 reductions	 in	cell	 viability	
(WP-06-2A,	86.1	± 1.8%;	WP-06-2B,	90	± 5.6%).	
The	toxicity	of	the	conjugates	on	fibroblast	cells	was	
significantly	lower	(p <	0.05)	than	that	of	paclitaxel.
Analysis of cell cycle. The	G2/M	ratio	increased	
from	13.4%	in	untreated	A549	cells	to	44.9%	in	A549	
cells	exposed	to	1	μmol/L	paclitaxel	for	24	h	(Fig.	3).	
Exposure	of	these	cells	to	1	μmol/L	of	two	conjugates	
for	24	h	increased	this	ratio	further	(WP-06-2A,	55.8%;	
WP-06-2B,	75.4%)	(see	Fig.	3).	
fig. 3. The cell	cycle	perturbations	of	A549	cells	determined	us-
ing	FACs	Scan	flow	cytometry	after	a	24	h	exposure	to	1	μmol/L	
paclitaxel,	WP-06-2A	and	WP-06-2B.	Control	(Con)	represents	
the	results	of	A549	cells	that	were	not	exposed	to	any	drugs
DIScuSSION
Over	 the	past	decade,	several	analogs	of	soma-
tostatin	have	been	developed	for	the	targeted	delivery	
of	chemotherapeutic	agents	and	antisense	peptide	
nucleic	 acids	 [25–28].	 In	 doing	 so,	 these	 recent	
advances	 in	 the	 synthesis	 and	evaluation	of	 such	
compounds	have	contributed	 to	 the	establishment	
of	the	concept	of	targeted	drug	therapy.	Remarkable	
progress	has	also	been	made	on	the	identification	of	
tumors	and	their	metastases	that	express	somatostatin	
receptors.	Current	preclinical	data	provide	good	evi-
dence	that	SSTR-positive	tumors	can	be	targeted	suc-
cessfully	in vivo	using	somatostatin	analogs	coupled	
to	chemotherapeutic	agents,	which	are	more	effective	
and	considerably	less	toxic	than	unconjugated	cyto-
toxic	radicals	[29].	The	anti-tumor	drug,	paclitaxel	is	
therapeutically	beneficial	for	NSCLC.	However,	it	is	not	
cell-specific,	which	 is	a	major	drawback.	Therefore,	
conjugates	of	octreotide	and	paclitaxel	may	be	useful	
for	targeted	drug	therapy	for	NSCLC.
Several	 investigators	have	 reported	 that	human	
NSCLC	may	overexpress	SSTRs	[5,	6].	However,	the	
expression	of	SSTRs	by	NSCLC	cell	lines	remains	con-
troversial.	In	agreement	with	the	results	of	Ferone	et	al	
[7],	we	detected	mRNA	for	SSTR-2	and	SSTR-5 in	Calu-
6	cells	and	the	expression	of	SSTR-5	was	greater	than	
that	of	SSTR-2.	We	found	mRNA	for	SSTR1	and SSTR4	
in	Calu-6	cells.	Nayak	et	al	[17]	reported	that	A549	cells	
do	not	express	SSTRs.	Given	this	result,	we	intended	
to	use	A549	cells	as	a	SSTR-negative	control	cell	line.	
However,	we	established	that	these	cells	expressed	all	
the	subtypes of	SSTR	except	SSTR-3.	Furthermore,	
we	found	that	the	expression	of	SSTR-2	was	more	pro-
nounced	than	that	of	SSTR-5.	As	a	result,	we	had	two	
cells	that	we	could	use	to	evaluate	the	targeted	delivery	
of	paclitaxel	using	an	octreotide	carrier.
In	our	experiment,	WP-06-2A	and	WP-06-2B	inhib-
ited	the	growth	of	A549	and	Calu-6	cells	in	a	concentra-
tion-	and	time-dependent	manner	and	the	suppression	
of	cell	growth	was	potentiated	at	the	higher	concentra-
tions.	When	the	exposure	time	was	extended	to	72	h,	
the	viabilities	of	A549	and	Calu-6	cells	were	extremely	
low.	FACS	analysis	showed	that	the	G2/M	ratio	in	A549	
cells	in	the	presence	of	1	μmol/L	paclitaxel	or	the	conju-
gates	for	24	h	increased.	The	result	indicated	that	both	
WP-06-2A	and	WP-06-2B	maintained	the	cytotoxicity	
of	paclitaxel.	Within	our	experiment,	we	showed	that	
SSTR-negative	fibroblasts,	WP-06-2A	and	WP-06-2B	
were	 less	cytotoxic	 than	paclitaxel.	When	A549	cells	
were	pretreated	with	excess	octreotide,	the	cytotoxici-
ties	of	both	WP-06-2A	and	WP-06-2B	decreased	and	
the	cytotoxicity	of	paclitaxel	 increased.	These	results	
show	that	WP-06-2A	and	WP-06-2B	can	bind	selec-
tively	to	SSTRs	and	cause	cell	death	specially	[25,	29].	
Because	WP-06-2A	and	WP-06-2B	were	cytotoxic	 in	
tumor	cells	expressing	SSTRs,	we	suggest	 that	 the	
development	of	paclitaxel-octreotide	conjugates	may	
be	valuable	for	targeted	therapy	of	NSCLC.
The	different	expressions	of	SSTRs	influenced	the	
cytotoxicity	of	WP-06-2B.	In	A549	cells,	which	overex-
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press	SSTR-2,	the	cytotoxic	potency	of	WP-06-2B	was	
greater	than	that	of	paclitaxel	at	low	concentrations.	In	
Calu-6	cells,	which	overexpress	SSTR-5,	100	nmol/L	
WP-06-2B	was	 less	cytotoxic	 than	paclitaxel.	How-
ever,	the	different	expressions	of	mRNA	for	SSTR-2	
and	SSTR-5	have	little	influence	on	the	cytotoxicity	of	
WP-06-2A.	When	compared	 to	 the	cytotoxic	effects	
of	free	paclitaxel,	the	cytotoxic	effects	of	WP-06-2A	
were	similar	 in	A549	and	Calu-6	cells,	but	were	less	
toxic	in	fibroblasts.	Culler	et	al	[30]	reported	that	the	
affinity	of	octreotide	 for	SSTR-2	 is	 higher	 than	 its	
affinity	 to	SSTR-5.	Therefore,	 the	affinity	of	WP-06-
2B	 for SSTR-2	might	be	greater	 than	 its	affinity	 for	
SSTR-5.	This	difference	in	affinity	could	account	for	
the	different	cytotoxicity	of	WP-06-2B	 in	A549	and	
Calu-6	cells	because	of	the	different	expressions	of	
mRNA	for	SSTR-2	and	SSTR-5	in	the	two	cell	 lines.	
When	tumor	tissue	over-expresses	mRNA	for	SSTR-2,	
one	might	expect	 that	WP-06-2B	would	have	more	
potent	antitumor	effects	and	 less	 toxic	side	effects	
than	WP-06-2A.	Further	investigations	are	needed	to	
assess	the	biological	properties	of	WP-06-2B	in vivo.
There	was	an	interesting	result	in	our	experiment.	
All	the	drugs	caused	precipitates	in	cell	culture	media	
when	10	μmol/L	concentrations	were	used.	The	vi-
ability	of	A549	cells	that	were	exposed	to	10	μmol/L	
paclitaxel	was	the	same	as	that	of	A549	cells	treated	
with	1	μmol/L	paclitaxel.	 Yet,	 the	viabilities	of	A549	
cells	that	were	exposed	to	10	μmol/L	WP-06-2A	and	
WP-06-2B	progressively	decreased	and	were	 lower	
than	those	of	cells	exposed	to	10	μmol/L	paclitaxel.	
It	is	known	that	the	aqueous	solubility	of	paclitaxel	is	
extremely	low	[20]	and	octreotide	is	water-soluble	[20,	
31].	Therefore,	 the	higher	cytotoxicity	of	 the	conju-
gates	might	be	due	to	their	being	more	water-	solubility	
than	paclitaxel	in	aqueous	cell	culture	medium.	
Schally	et	al.	[10,	32]	have	developed	a	cytotoxic	
analog	of	somatostatin,	AN-238,	 in	which	 the	soma-
tostatin	carrier	peptide	RC-121	was	linked	to	2-pyrro-
lino-doxorubicin	(AN-201),	which	is	a	potent	derivative	
of	doxorubicin.	When	compared	to	AN-201,	they	found	
that	AN-238	was	more	effective	and	 less	 toxic	 in	a	
NSCLC	H-838	xenogenic	graft	 in	nude	mice.	Moody	
et	al	[8]	synthesized	camptothecin-somatostatin	con-
jugate	by	linking	camptothecin	to	the	amino	terminal	of	
somatostatin	analog	and	reported	that	the	conjugate	
inhibited	the	growth	of	human	small	cell	 lung	cancer	
cells.	Huang	et	al.	 [25]	synthesized	octreotide-con-
jugated	paclitaxel	by	coupling	paclitaxel	succinate	to	
the	amino	terminal	of	octreotide.	When	comparing	the	
effects	of	free	paclitaxel	in	human	breast	MCF-7	car-
cinoma	cells,	they	showed	that	octreotide-conjugated	
paclitaxel	retained	the	biological	activity	of	paclitaxel	by	
inducing	the	formation	of	tubulin	bundles	and	eventually	
causing	apoptosis.	All	of	our	experimental	results	were	
obtained	using	cultured	cell	systems.	Given	our	results,	
further	research	on	in vivo	cell	selectivity	and	cytotoxic-
ity	of	WP-06-2A	and	WP-06-2B	is	warranted.		
In	conclusion,	 the	 results	of	 this	study	show	 that	
NSCLC	cell	lines,	such	as	A549	and	Calu-6	cells,	ex-
press	SSTRs.	 Irrespective	of	whether	paclitaxel	suc-
cinate	was	coupled	to	the	amino	acid	end	and/or	the	
free	amino	terminus	of	lysine	of	octreotide,	WP-06-2A	
and	WP-06-2B	were	potent	inhibitors	of	cell	growth	of	
NSCLC	cells	in vitro.	These	results	suggest	strongly	that	
conjugates	of	somatostatin	analogs	and	paclitaxel	could	
be	used	as	efficacious	agents	 for	selective	 targeted	
cancer	chemotherapy in vitro	and	could	be	a	promising	
therapeutic	modality	for	the	treatment	of	NSCLC.		
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КОНЪЮГАТЫ ПАКЛИТАКСЕЛА-ОКТРЕОТИДА ИНГИБИРУЮТ 
РОСТ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО in vitro
Цель: оценить эффект конъюгатов паклитаксела-октреотида на рост культивированных клеток немелкоклеточного рака 
легкого человека. Методы: для определения мРНК подтипов рецептора соматостатина человека (SSTR) применяли ОT-ПЦР. 
Анализ цитотоксичности в МТТ-тесте применяли для оценки выживаемости клеток после их инкубации с паклитакселом 
и конъюгатами. Нарушения клеточного цикла определяли с применением FACS — клеточного сортера. Результаты: 
установлено, что клеточные линии немелкоклеточного рака легкого A549 и Calu-6 экспрессируют SSTR2 и SSTR5 мРНК. 
Отмечено эффективное дозо- и времязависимое угнетение роста клеток A549 и Calu-6 паклитакселом и конъюгатами. 
Для SSTR-негативных фибробластов конъюгаты менее цитотоксичны, чем паклитаксел. Конъюгаты и паклитаксел могут 
индуцировать повышение соотношения фаз G2/M в клетках A549. Выводы: конъюгаты паклитаксел-октреотида могут быть 
использованы как селективные химиотерапевтические агенты для воздействия на немелкоклеточный рак легкого. 
Ключевые слова: немелкоклеточный рак легкого, октреотид, паклитаксел.
